Carnosine
CAS 305-84-0
Purity≥98.0%
Dipeptide material for muscle and cellular-aging research
L-Carnosine Powder (CAS 305-84-0), specification ≥98.0%. L-Carnosine is a dipeptide of beta-alanine and L-histidine, supplied with ingredient identity and batch assay documentation. Batch COA and evaluation samples are available. MOQ: 1 kg. nutrition & functional ingredients
Quote / sample & delivery
Key Specifications
| Product Positioning | Dipeptide material for muscle and cellular-aging research |
| Application Scenarios | dipeptide cell research · sports-nutrition formulation · water-based cosmetic screening |
| CAS Number | 305-84-0 |
| Purity | ≥98.0% |
| Molecular Formula | C₉H₁₄N₄O₃ |
| Molecular Weight | 226.23 g/mol |
| Appearance | White crystalline powder |
| Solubility | Freely soluble in water |
| Storage | Room temperature, dry |
| Shelf Life | 36 months |
Procurement & delivery
Supply details confirmed by intended use, volume and target market
L-Carnosine is a naturally occurring dipeptide formed from the amino acids beta-alanine and L-histidine (CAS 305-84-0; molecular formula C9H14N4O3; MW 226.23 g/mol). It occurs endogenously at high concentrations in the skeletal muscle, cardiac tissue, and brain of vertebrates, where it contributes to intracellular pH buffering and cellular protection. For commercial supply, bulk L-carnosine is produced through a biotechnology-based route: the two precursor amino acids, L-histidine and beta-alanine, are first obtained by microbial fermentation, then joined through a controlled enzymatic coupling step that forms the characteristic beta-amino peptide bond. The resulting dipeptide is purified by crystallization and dried into a white crystalline powder of ≥98.0% purity, suitable for dietary supplement, cosmetic, and pharmaceutical-grade raw material applications.
High, Verified Purity
Each production batch is assayed at ≥98.0% purity by HPLC, with a batch-specific certificate of analysis issued for every shipment.
Controlled Bio-Based Production
Precursor amino acids are produced via microbial fermentation and joined through a tightly controlled enzymatic coupling process, reducing residual solvents and by-products versus purely chemical routes.
Consistent Crystalline Form
Supplied as a free-flowing white crystalline powder with consistent particle size, appearance, and odor from batch to batch.
Full Contaminant Screening
Every lot is screened for heavy metals (Pb, Hg, Cd, As) and microbial limits to meet food-grade, cosmetic-grade, and pharmaceutical raw material requirements.
Flexible Bulk & OEM Supply
Available in bulk quantities with customizable packaging, particle size, and private-label documentation to support OEM/ODM programs.
Test items, specifications and results for the listed batch are shown here. View or request a COA in the quality documents section.
Batch No.
PG04-260522
Test date
2026-05-23
Specification
In-house
Pack size
25kg/carton
Storage
Room temperature, dry
Conclusion
Conforms
| Test Item | Specification | Result |
|---|---|---|
| Appearance | White crystalline powder | Conforms |
| Odor | Characteristic, no off-odor | Conforms |
| Assay (HPLC) | ≥98.0% | 99.1% |
| pH (1% aqueous solution) | 7.0 - 8.5 | 7.8 |
| Loss on Drying | ≤0.5% | 0.22% |
| Particle Size / Crystal Form | Fine crystalline powder, through 80 mesh ≥95% | Conforms |
| Lead (Pb) | ≤2 mg/kg | <1 mg/kg |
| Arsenic (As) | ≤2 mg/kg | <1 mg/kg |
| Mercury (Hg) | ≤1 mg/kg | <0.5 mg/kg |
| Cadmium (Cd) | ≤1 mg/kg | <0.5 mg/kg |
| Total Plate Count | ≤1000 CFU/g | <100 CFU/g |
| Yeast & Mold | ≤100 CFU/g | <10 CFU/g |
| E. coli | Negative/25 g | Negative |
| Salmonella | Negative/25 g | Negative |
View an available COA in the quality documents section. Check the document for its product form and batch; request a signed COA for your purchasing or shipment batch separately.
Hard capsules
Powders
Softgels
Tablets
Sublingual tablets
Oral dissolving films
Serum
Cream
Sheet masks
Keep L-carnosine identity separate from beta-alanine/histidine; validate oral and topical formats independently.
99.1%
Assay (HPLC)
PG04-260522 · Results apply to this lot; interpret purity, assay and water on their respective bases.
Composition candidates, processing sequences and tests support pilot design. Confirm candidate excipients and processes using this material in the actual finished formulation.
Application examples follow the materials, formats and findings actually studied. Combination studies, single-ingredient studies, commercial precedents and development candidates are distinguished.
Anserine and L-carnosine are distinct dipeptides with an oral-combination precedent, requiring separate identities and assays.
Show research and formulation insights +Hide details −Combination / selection rationale: Anserine and L-carnosine are distinct dipeptides with an oral-combination precedent, requiring separate identities and assays.
Published evidence / source details: A 12-week 2019 trial randomized 54 people with mild cognitive impairment to 750 mg anserine plus 250 mg carnosine daily or placebo. Global CDR differed, while most other cognitive tests did not improve overall.
Development insights: Qualify both dipeptide sources and assays; use mass-content values rather than chromatographic area directly for loading. Verify peak separation, uniformity, fill mass and disintegration after source changes.
Evidence scope: A pilot of a specified blend, without isolated-carnosine attribution or a disease-treatment claim.
2019 · Anserine/carnosine trial · DOI 10.3390/nu11071626 ↗A cream matrix and delivery affect evaluation; aqueous ingredient data cannot substitute for a complete topical formula.
Show research and formulation insights +Hide details −Combination / selection rationale: A cream matrix and delivery affect evaluation; aqueous ingredient data cannot substitute for a complete topical formula.
Published evidence / source details: A 2018 human-skin-explant study induced glycation with methylglyoxal and compared aqueous carnosine with a carnosine cream using CML and pentosidine endpoints; formulation affected results.
Development insights: Compare aqueous, blank-base and complete-cream samples at matched carnosine concentration. Check recovery, pH, preservation and retention; distinguish chemical/explant glycation endpoints from human appearance measures.
Evidence scope: Ex-vivo skin evidence, not human antiwrinkle or oral efficacy validation.
2018 · Facial cream / skin-explant study · DOI 10.1159/000492276 ↗Carbonyl-stress and redox endpoints can be studied separately, alongside partner solubility and assay compatibility.
Show research and formulation insights +Hide details −Combination / selection rationale: Carbonyl-stress and redox endpoints can be studied separately, alongside partner solubility and assay compatibility.
Published evidence / source details: The explant study demonstrates the importance of the matrix, without validating arbitrary vitamin-C, vitamin-E or other antioxidant blends.
Development insights: Use individual-actives, blend and blank controls. Dissolve aqueous partners separately and establish dispersion/emulsification for lipophilic partners; assay each active before comparing glycation and oxidation endpoints.
Evidence scope: Retains the antioxidant-blend concept as a development candidate, separating oral and topical evidence.
2018 · Related carnosine/matrix reference · skin-explant study ↗Literature-Supported Research Directions
Carnosine is studied in carbonyl stress, advanced glycation end-products (AGEs) and cytoprotection, including protein cross-linking, oxidative stress and tissue-aging mechanisms.
Citation: Narda et al. Novel Facial Cream Containing Carnosine Inhibits Formation of Advanced Glycation End-Products in Human Skin. Skin pharmacology and physiology (2018). PMID: 30199874.View source
Carnosine contributes to skeletal-muscle pH buffering and is studied in high-intensity exercise. The cited review primarily examines increasing muscle carnosine through beta-alanine supplementation. Those findings do not establish that oral L-carnosine powder has equivalent absorption, muscle loading or performance effects; this remains a muscle-metabolism research context.
Citation: Derave et al. Muscle carnosine metabolism and beta-alanine supplementation in relation to exercise and training. Sports medicine (Auckland, N.Z.) (2010). PMID: 20199122.View source
Note: For ingredient R&D and scientific information; findings depend on model, dose, formulation and population and do not constitute a treatment claim or efficacy guarantee.
Lead Time
3–5business days
Standard products are generally in stock; confirm the exact lead time with us.
Minimum Order
1 kg
Samples, pilot trials, and commercial volumes are supported.
Foil Pouch
Sealed, moisture-protective inner packaging
Fiber Drum
Standard outer packaging for bulk transport
Bulk Shipping
Palletized and stretch-wrapped for protection
Ambient storage: foil pouch + fiber drum; temperature controlled: foil pouch + insulated box/carton. Confirm by product.
Custom packaging: Custom foil bags or HDPE drums, GMP label printing, and export documentation are available. Contact us for a quote.Images are packaging illustrations.
Certifications
Precursor Amino Acid Fermentation
Selected microbial strains ferment renewable feedstocks to produce the two building-block amino acids, L-histidine and beta-alanine, in separate fermentation streams.
Precursor Recovery and Purification
Fermentation broths are clarified, and each amino acid is recovered by ion-exchange chromatography and crystallization to high purity.
Enzymatic Dipeptide Coupling
Purified L-histidine and beta-alanine are combined under controlled temperature and pH in a biocatalytic coupling reaction that forms the beta-amino peptide bond characteristic of carnosine.
Reaction Quench and Clarification
The coupling reaction is quenched, and the crude solution is filtered to remove residual biomass, spent catalyst, and insoluble by-products.
Chromatographic Purification
The clarified solution undergoes ion-exchange and/or resin-based chromatography to remove unreacted precursors and trace impurities.
Crystallization
The purified carnosine solution is concentrated and crystallized under controlled cooling conditions to yield uniform crystals.
Drying and Milling
Crystals are dried under vacuum, then milled and sieved to achieve the target particle size and a free-flowing white powder.
Quality Control and Packaging
Each batch is tested against the full quality specification (assay, heavy metals, microbial limits) before being packaged under controlled conditions for shipment.
Purity is determined by high-performance liquid chromatography (HPLC), typically using a reverse-phase or ion-pair column referenced against a certified L-carnosine standard, with content calculated as the area percentage of the main peak. Buyers should confirm the specific HPLC method, mobile phase, and reference standard applied, and request a batch-specific certificate of analysis (COA) confirming the material meets the ≥98.0% purity specification before finalizing an order.
L-carnosine is freely soluble in water, making it well suited for aqueous formulations such as functional beverages, effervescent tablets, oral solutions, and water-based cosmetic serums. It is comparatively less soluble in ethanol and other organic solvents, so formulators working with anhydrous or oil-based systems may need co-solvents, micronized grades, or microencapsulation technology to improve dispersibility. As a zwitterionic dipeptide, its solubility and stability can be influenced by formulation pH and the presence of reducing sugars (Maillard-type interactions), which should be evaluated during product development.
Request the offered lot COA and agreed specification for CAS 305-84-0, including identity, assay basis and related-substance results. Confirm the method and reference standard before comparing quotations.
Verify L-carnosine manufacturing and animal-free sourcing through material-specific process information, source declarations and relevant excipient information. The batch COA documents identity, assay and quality results. Review source declarations separately from quality-release documents.
Yes, L-carnosine is freely soluble in water, which makes it suitable for beverages, effervescent products, and other aqueous formulations. Solubility in ethanol and oils is limited, so oil-based systems may require additional formulation support.
Yes, small samples are available on request for formulation trials and quality evaluation prior to committing to a bulk order.
Yes. We operate under our internal quality management system and are glad to accommodate third-party or customer-designated laboratory testing of samples prior to or after shipment.
Yes, we support OEM/ODM programs including custom labeling, private-label documentation, and packaging tailored to customer specifications.
Standard bulk packaging is in moisture-proof, double-lined drums or bags (e.g., 1 kg, 5 kg, and 25 kg), with custom sizes and packaging materials available on request.
The raw-material MOQ for L-carnosine powder is 1 kg, with pack options of 1 kg, 5 kg, 25 kg. Typical lead time is 3–5 business days, with dispatch confirmed for the order.
No. L-carnosine is beta-alanyl-L-histidine, a dipeptide; beta-alanine is one constituent amino acid. Equal powder mass does not establish an equivalent formulation.
Harris et al. (2006) reported increased muscle carnosine in both L-carnosine and beta-alanine groups under the study’s doses and four-week regimen. Formulation assessment should distinguish ingredient identity, molar quantity and study endpoints. These results do not guarantee exercise performance for an arbitrary finished product. Reference: PMID 16554972.
No. A related-substance result measures a separately specified free component; it is not the amino acid chemically joined within the dipeptide. Confirm the separation and reporting method.
No. Confirm the reference standard, calculation method, reporting basis and impurity separation. Chromatographic area percentage should not automatically be treated as mass content.
A human-skin-explant study compared aqueous carnosine and a carnosine cream using glycation endpoints. It supports comparing the ingredient with the complete topical matrix, not assuming human antiwrinkle efficacy. Match carnosine concentration, include a blank base, confirm assay recovery and measure pH, preservation and storage retention before interpreting the functional tests.
Documents are subject to product and batch availability; third-party reports are provided only when applicable.
Quality documents
The specification sheet defines acceptance limits. The COA shows actual batch results, which may vary by batch. Third-party reports are provided only for products or batches that have been independently tested.
Stable acceptance criteria · Available on request
Actual test data · Check the COA for the applicable batch
Technical Resources
Explore L-carnosine anti-glycation research, carbonyl trapping, human evidence, and practical checks for powder, capsule and tablet formulation.
Compare L-carnosine and beta-alanine identity and muscle research, then check bulk ingredient assay, related substances, matching COA and quotation requirements.
Related Products
Citicoline (CDP-Choline) Powder
Gamma-Aminobutyric Acid (GABA) Powder
Reduced L-Glutathione Powder (GSH)
Interested in Carnosine?
Our R&D team will respond to your inquiry or sample request within 24 hours.
Scan to add WeChat
Alex Huang · Mon–Fri 9am–6pm CST
